Loading…

Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accu...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in genetics 2023-01, Vol.13, p.1092678-1092678
Main Authors: Wu, Wenqi, Liu, Su, Tian, Linyan, Li, Cheng, Jiang, Yanan, Wang, Jinhuan, Lv, Yangyang, Guo, Jing, Xing, Donghui, Zhai, Yixin, Sun, Huimeng, Li, Yuhang, Zhang, Luying, He, Xiang, Luo, Kaiping, Zhan, Hongjie, Zhao, Zhigang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703
cites cdi_FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703
container_end_page 1092678
container_issue
container_start_page 1092678
container_title Frontiers in genetics
container_volume 13
creator Wu, Wenqi
Liu, Su
Tian, Linyan
Li, Cheng
Jiang, Yanan
Wang, Jinhuan
Lv, Yangyang
Guo, Jing
Xing, Donghui
Zhai, Yixin
Sun, Huimeng
Li, Yuhang
Zhang, Luying
He, Xiang
Luo, Kaiping
Zhan, Hongjie
Zhao, Zhigang
description Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accurate prognostic assessment needs further exploration. In the present study, we constructed a novel prognostic model based on microtubule associated genes (MAGs). A total of 33 normal controls and 1360 DLBCL samples containing gene-expression from the Gene Expression Omnibus (GEO) database were included. Subsequently, the univariate Cox, the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were used to select the best prognosis related genes into the MAGs model. To validate the model, Kaplan-Meier curve, and nomogram were analyzed. A risk score model based on fourteen candidate MAGs ( ) was established. The K-M curve presented that the high-risk patients had a significantly inferior overall survival (OS) time compared to low-risk patients in training and validation datasets. Furthermore, knocking-out , a key gene belonging to the MAGs model, inhibited cell proliferation noticeably. The novel MAGs prognostic model has a well predictive capability, which may as a supplement for the current assessments. Furthermore, candidate TMEM63A gene has therapeutic target potentially in DLBCL.
doi_str_mv 10.3389/fgene.2022.1092678
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_14a7411f32b34b9d94307d0f47f8cf4e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_14a7411f32b34b9d94307d0f47f8cf4e</doaj_id><sourcerecordid>2775621619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703</originalsourceid><addsrcrecordid>eNpVkUtP3DAQgC1UVBDlD_SAfOwlW7_ixJdKLWrLSki9lLPlxziYJvHWTirx7-tlFwS-eGTPfDOaD6GPlGw479XnMMAMG0YY21CimOz6E3ROpRRNTxh99yo-Q5elPJB6hOKci_fojMtOUqn4OZq2HuYlhujMEtOMU8BTdDktq11HaEwpyUWzgMc2psnkP5ALjjP2MYS1AB5NHgB_axyMIx4fp919zcJm9niX0zCnEkuNwEe3x39Ap8GMBS6P9wW6-_H99_VNc_vr5_b6623jhOyXJjjVGk4cZ5YEL3rhQFGgrG89D721RlFqHThrW-qtgrY11FMF0ApwsiP8Am0PXJ_Mg97lWCd_1MlE_fSQ8qBNXqIbQVNhOkFpqL24sMorwUnnSRBd6F0QUFlfDqzdaifwrq4rm_EN9O3PHO_1kP5ppQiTqquAT0dATn9XKIueYtnvy8yQ1qJZ17WSUUlVTWWH1GqglAzhpQ0leq9dP2nXe-36qL0WXb0e8KXkWTL_DxlTrXk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2775621619</pqid></control><display><type>article</type><title>Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction</title><source>PubMed Central Free</source><creator>Wu, Wenqi ; Liu, Su ; Tian, Linyan ; Li, Cheng ; Jiang, Yanan ; Wang, Jinhuan ; Lv, Yangyang ; Guo, Jing ; Xing, Donghui ; Zhai, Yixin ; Sun, Huimeng ; Li, Yuhang ; Zhang, Luying ; He, Xiang ; Luo, Kaiping ; Zhan, Hongjie ; Zhao, Zhigang</creator><creatorcontrib>Wu, Wenqi ; Liu, Su ; Tian, Linyan ; Li, Cheng ; Jiang, Yanan ; Wang, Jinhuan ; Lv, Yangyang ; Guo, Jing ; Xing, Donghui ; Zhai, Yixin ; Sun, Huimeng ; Li, Yuhang ; Zhang, Luying ; He, Xiang ; Luo, Kaiping ; Zhan, Hongjie ; Zhao, Zhigang</creatorcontrib><description>Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accurate prognostic assessment needs further exploration. In the present study, we constructed a novel prognostic model based on microtubule associated genes (MAGs). A total of 33 normal controls and 1360 DLBCL samples containing gene-expression from the Gene Expression Omnibus (GEO) database were included. Subsequently, the univariate Cox, the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were used to select the best prognosis related genes into the MAGs model. To validate the model, Kaplan-Meier curve, and nomogram were analyzed. A risk score model based on fourteen candidate MAGs ( ) was established. The K-M curve presented that the high-risk patients had a significantly inferior overall survival (OS) time compared to low-risk patients in training and validation datasets. Furthermore, knocking-out , a key gene belonging to the MAGs model, inhibited cell proliferation noticeably. The novel MAGs prognostic model has a well predictive capability, which may as a supplement for the current assessments. Furthermore, candidate TMEM63A gene has therapeutic target potentially in DLBCL.</description><identifier>ISSN: 1664-8021</identifier><identifier>EISSN: 1664-8021</identifier><identifier>DOI: 10.3389/fgene.2022.1092678</identifier><identifier>PMID: 36761693</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>DLBCL ; Genetics ; microtube-associated genes ; prognostic model ; targeting therapy ; TMEM63A</subject><ispartof>Frontiers in genetics, 2023-01, Vol.13, p.1092678-1092678</ispartof><rights>Copyright © 2023 Wu, Liu, Tian, Li, Jiang, Wang, Lv, Guo, Xing, Zhai, Sun, Li, Zhang, He, Luo, Zhan and Zhao.</rights><rights>Copyright © 2023 Wu, Liu, Tian, Li, Jiang, Wang, Lv, Guo, Xing, Zhai, Sun, Li, Zhang, He, Luo, Zhan and Zhao. 2023 Wu, Liu, Tian, Li, Jiang, Wang, Lv, Guo, Xing, Zhai, Sun, Li, Zhang, He, Luo, Zhan and Zhao</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703</citedby><cites>FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902697/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902697/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36761693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Wenqi</creatorcontrib><creatorcontrib>Liu, Su</creatorcontrib><creatorcontrib>Tian, Linyan</creatorcontrib><creatorcontrib>Li, Cheng</creatorcontrib><creatorcontrib>Jiang, Yanan</creatorcontrib><creatorcontrib>Wang, Jinhuan</creatorcontrib><creatorcontrib>Lv, Yangyang</creatorcontrib><creatorcontrib>Guo, Jing</creatorcontrib><creatorcontrib>Xing, Donghui</creatorcontrib><creatorcontrib>Zhai, Yixin</creatorcontrib><creatorcontrib>Sun, Huimeng</creatorcontrib><creatorcontrib>Li, Yuhang</creatorcontrib><creatorcontrib>Zhang, Luying</creatorcontrib><creatorcontrib>He, Xiang</creatorcontrib><creatorcontrib>Luo, Kaiping</creatorcontrib><creatorcontrib>Zhan, Hongjie</creatorcontrib><creatorcontrib>Zhao, Zhigang</creatorcontrib><title>Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction</title><title>Frontiers in genetics</title><addtitle>Front Genet</addtitle><description>Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accurate prognostic assessment needs further exploration. In the present study, we constructed a novel prognostic model based on microtubule associated genes (MAGs). A total of 33 normal controls and 1360 DLBCL samples containing gene-expression from the Gene Expression Omnibus (GEO) database were included. Subsequently, the univariate Cox, the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were used to select the best prognosis related genes into the MAGs model. To validate the model, Kaplan-Meier curve, and nomogram were analyzed. A risk score model based on fourteen candidate MAGs ( ) was established. The K-M curve presented that the high-risk patients had a significantly inferior overall survival (OS) time compared to low-risk patients in training and validation datasets. Furthermore, knocking-out , a key gene belonging to the MAGs model, inhibited cell proliferation noticeably. The novel MAGs prognostic model has a well predictive capability, which may as a supplement for the current assessments. Furthermore, candidate TMEM63A gene has therapeutic target potentially in DLBCL.</description><subject>DLBCL</subject><subject>Genetics</subject><subject>microtube-associated genes</subject><subject>prognostic model</subject><subject>targeting therapy</subject><subject>TMEM63A</subject><issn>1664-8021</issn><issn>1664-8021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtP3DAQgC1UVBDlD_SAfOwlW7_ixJdKLWrLSki9lLPlxziYJvHWTirx7-tlFwS-eGTPfDOaD6GPlGw479XnMMAMG0YY21CimOz6E3ROpRRNTxh99yo-Q5elPJB6hOKci_fojMtOUqn4OZq2HuYlhujMEtOMU8BTdDktq11HaEwpyUWzgMc2psnkP5ALjjP2MYS1AB5NHgB_axyMIx4fp919zcJm9niX0zCnEkuNwEe3x39Ap8GMBS6P9wW6-_H99_VNc_vr5_b6623jhOyXJjjVGk4cZ5YEL3rhQFGgrG89D721RlFqHThrW-qtgrY11FMF0ApwsiP8Am0PXJ_Mg97lWCd_1MlE_fSQ8qBNXqIbQVNhOkFpqL24sMorwUnnSRBd6F0QUFlfDqzdaifwrq4rm_EN9O3PHO_1kP5ppQiTqquAT0dATn9XKIueYtnvy8yQ1qJZ17WSUUlVTWWH1GqglAzhpQ0leq9dP2nXe-36qL0WXb0e8KXkWTL_DxlTrXk</recordid><startdate>20230124</startdate><enddate>20230124</enddate><creator>Wu, Wenqi</creator><creator>Liu, Su</creator><creator>Tian, Linyan</creator><creator>Li, Cheng</creator><creator>Jiang, Yanan</creator><creator>Wang, Jinhuan</creator><creator>Lv, Yangyang</creator><creator>Guo, Jing</creator><creator>Xing, Donghui</creator><creator>Zhai, Yixin</creator><creator>Sun, Huimeng</creator><creator>Li, Yuhang</creator><creator>Zhang, Luying</creator><creator>He, Xiang</creator><creator>Luo, Kaiping</creator><creator>Zhan, Hongjie</creator><creator>Zhao, Zhigang</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230124</creationdate><title>Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction</title><author>Wu, Wenqi ; Liu, Su ; Tian, Linyan ; Li, Cheng ; Jiang, Yanan ; Wang, Jinhuan ; Lv, Yangyang ; Guo, Jing ; Xing, Donghui ; Zhai, Yixin ; Sun, Huimeng ; Li, Yuhang ; Zhang, Luying ; He, Xiang ; Luo, Kaiping ; Zhan, Hongjie ; Zhao, Zhigang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>DLBCL</topic><topic>Genetics</topic><topic>microtube-associated genes</topic><topic>prognostic model</topic><topic>targeting therapy</topic><topic>TMEM63A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Wenqi</creatorcontrib><creatorcontrib>Liu, Su</creatorcontrib><creatorcontrib>Tian, Linyan</creatorcontrib><creatorcontrib>Li, Cheng</creatorcontrib><creatorcontrib>Jiang, Yanan</creatorcontrib><creatorcontrib>Wang, Jinhuan</creatorcontrib><creatorcontrib>Lv, Yangyang</creatorcontrib><creatorcontrib>Guo, Jing</creatorcontrib><creatorcontrib>Xing, Donghui</creatorcontrib><creatorcontrib>Zhai, Yixin</creatorcontrib><creatorcontrib>Sun, Huimeng</creatorcontrib><creatorcontrib>Li, Yuhang</creatorcontrib><creatorcontrib>Zhang, Luying</creatorcontrib><creatorcontrib>He, Xiang</creatorcontrib><creatorcontrib>Luo, Kaiping</creatorcontrib><creatorcontrib>Zhan, Hongjie</creatorcontrib><creatorcontrib>Zhao, Zhigang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Wenqi</au><au>Liu, Su</au><au>Tian, Linyan</au><au>Li, Cheng</au><au>Jiang, Yanan</au><au>Wang, Jinhuan</au><au>Lv, Yangyang</au><au>Guo, Jing</au><au>Xing, Donghui</au><au>Zhai, Yixin</au><au>Sun, Huimeng</au><au>Li, Yuhang</au><au>Zhang, Luying</au><au>He, Xiang</au><au>Luo, Kaiping</au><au>Zhan, Hongjie</au><au>Zhao, Zhigang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction</atitle><jtitle>Frontiers in genetics</jtitle><addtitle>Front Genet</addtitle><date>2023-01-24</date><risdate>2023</risdate><volume>13</volume><spage>1092678</spage><epage>1092678</epage><pages>1092678-1092678</pages><issn>1664-8021</issn><eissn>1664-8021</eissn><abstract>Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with a complicated prognosis. Even though various prognostic evaluations have been applied currently, they usually only use the clinical factors that overlook the molecular underlying DLBCL progression. Therefore, more accurate prognostic assessment needs further exploration. In the present study, we constructed a novel prognostic model based on microtubule associated genes (MAGs). A total of 33 normal controls and 1360 DLBCL samples containing gene-expression from the Gene Expression Omnibus (GEO) database were included. Subsequently, the univariate Cox, the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis were used to select the best prognosis related genes into the MAGs model. To validate the model, Kaplan-Meier curve, and nomogram were analyzed. A risk score model based on fourteen candidate MAGs ( ) was established. The K-M curve presented that the high-risk patients had a significantly inferior overall survival (OS) time compared to low-risk patients in training and validation datasets. Furthermore, knocking-out , a key gene belonging to the MAGs model, inhibited cell proliferation noticeably. The novel MAGs prognostic model has a well predictive capability, which may as a supplement for the current assessments. Furthermore, candidate TMEM63A gene has therapeutic target potentially in DLBCL.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>36761693</pmid><doi>10.3389/fgene.2022.1092678</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-8021
ispartof Frontiers in genetics, 2023-01, Vol.13, p.1092678-1092678
issn 1664-8021
1664-8021
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_14a7411f32b34b9d94307d0f47f8cf4e
source PubMed Central Free
subjects DLBCL
Genetics
microtube-associated genes
prognostic model
targeting therapy
TMEM63A
title Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A30%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20microtubule-associated%20biomarkers%20in%20diffuse%20large%20B-cell%20lymphoma%20and%20prognosis%20prediction&rft.jtitle=Frontiers%20in%20genetics&rft.au=Wu,%20Wenqi&rft.date=2023-01-24&rft.volume=13&rft.spage=1092678&rft.epage=1092678&rft.pages=1092678-1092678&rft.issn=1664-8021&rft.eissn=1664-8021&rft_id=info:doi/10.3389/fgene.2022.1092678&rft_dat=%3Cproquest_doaj_%3E2775621619%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-fc95a30c32b0fd484ce91e1285d3f8bba911bcecbb51db9e55a1d19ee54ec6703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2775621619&rft_id=info:pmid/36761693&rfr_iscdi=true